Plavix® Lawsuits Pending in New Jersey MDL
Plaintiffs throughout the country have filed lawsuits against drug makers Bristol-Myers Squibb and Sanofi-Aventis claiming they have suffered various injuries from the use of Plavix®, including cerebral hemorrhaging (brain bleeding) and gastrointestinal hemorrhaging (abdominal bleeding).
Plavix® was approved in 1997 and is commonly prescribed to patients at risk for heart attack, stroke, or blood clotting. It is often prescribed along with a low-dose aspirin regimen for patients at high risk for heart attack. It is alleged that the manufacturers promoted Plavix® as being more effective than aspirin, albeit the lower risk of complications associated with aspirin, in preventing blood platelets from sticking together and forming clots.
In February, the United States Judicial Panel on Multidistrict Litigation (JPML) decided to consolidate all Plavix® lawsuits filed in the federal court system before the Honorable Judge Freda L. Wolfson in the United States District Court of New Jersey for coordinated pretrial purposes. Currently, there are 37 Plavix® lawsuits pending in this Multidistrict Litigation (In re: Plavix® Products Liability, MDL 2418).
Legal Disclaimer: The choice of a lawyer is an important decision and should not be based solely on advertisements.